Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer (NCT02516241)

🧪 Interventions in This Study

• MEDI4736 (Durvalumab) (DRUG)
• Tremelimumab (DRUG)
• Cisplatin (DRUG)
• Carboplatin (DRUG)
• Gemcitabine (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (222 Sites)

Showing the first 25 of 222 sites.

• Research Site — Los Angeles, California
• Research Site — Stanford, California
• Research Site — Aurora, Colorado
• Research Site — New Haven, Connecticut
• Research Site — Tampa, Florida
• Research Site — Atlanta, Georgia
• Research Site — Louisville, Kentucky
• Research Site — Boston, Massachusetts
• Research Site — Ann Arbor, Michigan
• Research Site — Detroit, Michigan
• Research Site — Omaha, Nebraska
• Research Site — New York, New York
• Research Site — New York, New York
• Research Site — Memphis, Tennessee
• Research Site — Nashville, Tennessee
• Research Site — Seattle, Washington
• Research Site — Box Hill,
• Research Site — Elizabeth Vale,
• Research Site — Macquarie University,
• Research Site — St Leonards,
• Research Site — Waratah,
• Research Site — Linz,
• Research Site — Vienna,
• Research Site — Vienna,
• Research Site — Brussels,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Urothelial Cancer

• Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer — Chandler, Arizona
• A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations — Anchorage, Alaska
• A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer — Cleveland, Ohio
• A Genotype-Phenotype Urothelial Cancer Registry — Basking Ridge, New Jersey
• Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies — Bethesda, Maryland

Explore by condition: All Urothelial Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.